We have merged with Viewpoint Molecular Targeting to become
Click here for the details
Cesium-131 is a proven, minimally invasive treatment designed to treat a variety of cancers with precision.
A diagnosis is the first step towards treating your cancer.
With the many advances and options in cancer treatment, determining what is right for you can feel overwhelming.
Isoray is here to help.
We’re committed to providing a powerful, proven treatment while connecting you with the very best care teams available.
Years of Data
Patients Treated
Day Half Life
Treats cancer at the source
Higher energy, greater coverage
Shorter half-life for rapid resolution of side-effects
Speed of Delivery
“Cesium-131 provides everything we want for prostate brachytherapy as both a monotherapy and in combination therapy, including delivery of a high dose of radiation more quickly for high risk patients in a low dose rate ‘setting.’”
Unlock the full benefits of MRI-based treatment planning and post-implant quality assurance with Cesium-131. Now FDA-cleared for pairing with the Sirius® MRI Marker.
About Us
Isoray develops innovative, personalized brachytherapy products that effectively treat many forms of cancer.
Blog
The Merger: Paving the Way for Tomorrow
By CEO Lori Woods We began this journey with a simple truth. Standing still is never an option. And the history of Isoray underscores that reality. When Isoray was founded, we were focused on the treatment of prostate cancer utilizing Cesium-131....
Press Releases
Initial Results From First Patient Dosed With Perspective Therapeutics’ Lead Drug VMT-α-NET Presented at The Treatment of Neuroendocrine Disorders at the 2023 PET/RTRC Annual Workshop Scientific Session
The result from first patient dosed with VMT-α-NET in India on a compassionate use basis showed favorable responses. The initial response was measured by a somatostatin imaging agent 68Ga-DOTANOC and demonstrated surprisingly favorable results...
Whether you’re a Patient or a Clinician,
we’re here to help.
Call us at 1-509-375-5329